May 7th 2024
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Marwan G. Fakih, MD, Discusses Regorafenib Plus Nivolumab in CRC and Multidisciplinary Care
July 9th 2021CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.
Clinical Trials in Progress: COMMIT Study
July 4th 2021NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).
Patients With Advanced CRC May Experience Survival Benefit With Lenvatinib Plus Pembrolizumab Combo
June 4th 2021Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.
Andreana N. Holowatyj, PhD, MS, on Rising Rates of Early-Onset Colorectal Cancer Worldwide
April 30th 2021The lead author spoke about the rising incidence of early-onset colorectal cancer, which was the focal point of her research presented at the American Association for Cancer Research Annual Meeting 2021.
Complete Mesocolic Excision is a Safe Option in Laparoscopic Right Hemicolectomy
April 7th 2021Early safety data from the RELARC trial showed complete mesocolic excision doesn’t increase intraoperative and postoperative complications of laparoscopic right hemicolectomy compared with D2 dissection when done by an experienced surgeon.
KRAS Mutations in Unresectable Colorectal Liver Metastases Linked to Reduced Response Rates
March 18th 2021Based on a single-institution study, investigators were able to correlate outcomes for unresectable colorectal liver metastases with the addition of hepatic arterial infusion pump therapy to systemic therapy to the presence of a mutation in KRAS.
Study Identifies Associations Between Low CRC Risk and Prudent Dietary Patterns
March 1st 2021“Emerging evidence supports a possible role for overall dietary patterns that, in totality, emphasize habitually consuming fruits, vegetables, grains, and low-fat dairy and reducing red meat and alcohol intake,” wrote the study authors.